Certified by Founder Lodge
Amgen
United States - Thousand Oaks, CA
INVESTOR
1 Disclosed Funding Rounds $112,000,000
9 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.
| Company | Date | Round | Raised |
|---|---|---|---|
 Neumora |
October, 17 ,2022 | Series B | $112,000,000 |
 ImmunoScape |
September, 26 ,2022 | Unknown | $14,000,000 |
 CancerIQ |
March, 04 ,2022 | Series B | $14,000,000 |
 Feldan Therapeutics |
June, 14 ,2023 | Series B | $16,500,000 |
 Generate:Biomedicines |
September, 18 ,2023 | Series C | $273,000,000 |
 ReCode Therapeutics |
September, 20 ,2023 | Series B | $50,000,000 |
 Culmination Bio |
December, 01 ,2023 | Unknown | $10,000,000 |
 Seismic Therapeutic |
December, 05 ,2023 | Series B | $121,000,000 |
 Quantinuum |
January, 17 ,2024 | Unknown | $300,000,000 |
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
Sizable Energy | $8,000,000 | (Oct 24, 2025)
Sumble | $38,500,000 | (Oct 24, 2025)
Syntracts | $5,300,000 | (Oct 24, 2025)
Cybrid | $10,000,000 | (Oct 24, 2025)
Elevara Medicines | $70,000,000 | (Oct 24, 2025)
